For the estimated 3.5 million people worldwide on dialysis, protein intake decisions carry outsized consequences — inadequate protein accelerates muscle wasting, while excess protein burdens failing kidneys. A new multicenter cohort study challenges a simple assumption: that stricter protein restriction during incremental peritoneal dialysis (iPD) meaningfully harms nutritional status compared with more liberal protein allowances.
The I-COPE PD interim analysis enrolled 205 iPD patients (mean age 63.3 years; 30% diabetic) across multiple centers and tracked albumin, BMI, and metabolic markers at baseline, six months, and twelve months. Patients were stratified by prescribed protein intake: at or below 0.6 g/kg/day versus above that threshold. Roughly 45% received the lower-protein prescription. Over twelve months, both groups exhibited a nearly identical albumin trajectory — an early decline followed by stabilization — with no statistically significant divergence (p = 0.647), and BMI tracked similarly (p = 0.461). Crucially, the rate at which patients remained on incremental rather than full-dose PD was statistically indistinguishable between groups. However, the lower-protein cohort did exhibit differences in certain metabolic parameters that the full publication details.
This finding sits at an important intersection of renal nutrition and dialysis adequacy research. The prevailing clinical concern has been that very low protein diets (≤0.6 g/kg/day) — acceptable for conservative CKD management — might be inappropriate once dialysis begins, given dialysis-related amino acid losses. These data suggest nutritional outcomes at one year may be more resilient to protein prescription level than assumed, though several caveats demand caution. The study is observational, not randomized, meaning protein prescriptions followed local protocols rather than controlled allocation. Self-reported dietary adherence is notoriously imprecise in renal patients, and 205 participants across heterogeneous centers limits statistical power for subgroup effects. The interim nature of the analysis also means longer-term outcomes — muscle mass trajectory, hospitalizations, mortality — remain unresolved. Confirmatory randomized data are needed before this changes clinical guidance.
